Background: To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule.
Introduction
In patients with metastatic CRC, 5-fluorouracil (5-FU) remains the key agent in first-line chemotherapy more than 40 years after introduction [1] [2] [3] . However, the prognosis for patients who fail to respond to 5-FUbased regimens is poor with a median survival around 6.5 months [4] . Primary and secondary clinical resistance to 5-FU has been linked to thymidylate synthase expression (TS) [5, 6] . Both CPT-11 and oxaliplatin are active in CRC patients and have TS-independent mechanisms of cytotoxicity.
CPT-11 (Campto®, Laboratoires Rhone-Poulenc Rorer, Montrouge, France) is a camptothecin derivative and a DNA topoisomerase I poison [7] . The lack of cross-resistance between CPT-11 and 5-FU when administered in the second-line setting is well documented [8, 9] . The addition of CPT-11 to 5-FU/folinic acid for first-line treatment of metastatic CRC patients significantly increased the objective response rate and the time to progression in two controlled studies [10, 11] and improved survival in one of them [10] .
Oxaliplatin (Eloxatine®, Sanofi-Synthelabo, Paris, France) is a platinum derivative with a 1,2 DACH carrier [12] . The addition of oxaliplatin to the 5-FUfolinic acid (FA) combination in advanced CRC patients was consistently found to at least double the response rate and significantly increase the time to tumor progression in two phase III clinical trials [13, 14] .
In vitro synergistic activity has been described between SN-38, the active metabolite of CPT-11, and oxaliplatin [15] . More cytotoxicity was consistently found in vitro giving oxaliplatin prior to or concurrently with the camptothecin derivative [15, 16] . The in vitro synergy could be related in part to more profound DNA and RNA synthesis inhibtions [15] and to a slower reversion of platinum-induced DNA interstrand-crosslinks [15, 16] .
The first phase I studies combining these two agents were done in Paul Brousse and St Louis hospitals (Villejuif and Paris, France), using an every three weeks schedule [17] . Acute DLTs were CPT-11-induced severe diarrhea and febrile neutropenia, and the cumulative DLT was oxaliplatin-related peripheral neuropathy. No plasma pharmacokinetic interactions between CPT-11 and oxaliplatin were detected. Using this schedule, the recommended doses were established at 85 mg/m 2 for oxaliplatin and 200 mg/m 2 for CPT-11 [17] . The weekly administration of 80 mg/m 2 of CPT-11 has been combined with an every other week administration of 85 mg/m 2 of oxaliplatin [18] . Consistently with the phase I studies of weekly administrations of CPT-11, gastrointestinal symptoms constituted the dose-limiting side-effects of the combination. However, neutropenia was also frequently severe and 31 out of 36 patients required prophylactic administration of G-CSF. A 42% response rate was reported in this cohort of 36 5-FU resistant CRC patients [18] .
Oxaliplatin and CPT-11 are both routinely combined with 5-FU/FA using an every two weeks schedule [10, 11, 13, 14] as first-line therapy in metastatic colorectal cancer patients. Hence, an approach to increase CPT-11 and oxaliplatin dose-intensities is to develop an every other week administration of both CPT-11 and oxaliplatin.
We initiated this phase I study to evaluate the toxicity of this schedule in patients with advanced digestive malignancies. The objectives were to determine the MTD of CPT-11 when combined with a fixed dose of 85 mg/m 2 of oxaliplatin and to define the DLTs of the combination. The dose of 85 mg/m 2 of oxaliplatin corresponded to the recommended dose of oxaliplatin with CPT-11 using the every three weeks schedule and is the dose favored in the two weeks schedules of oxaliplatin with 5-FU/FA. A secondary objective was to describe antitumor activity, focusing in 5-FU-resistant colorectal cancer patients.
Patients and methods

Patient eligibility
The inclusion criteria were those commonly used for phase I clinical trials. Patients with gastrointestinal malignancies, either having failed standard treatment or without validated therapeutic option, were selected based on the eligibility criteria previously described for the every three weeks schedule, which was the first part of this CPT-11/ oxaliplatin combination trial [17] . The main points were: performance status (WHO) < 2; adequate hepatic, renal, and bone marrow functions as previously defined [17] . Prior chemotherapy with oxaliplatin or CPT-11, previous malignancy, peripheral neuropathy, concomitant and uncontrolled non-malignant disease, including active infection, prior history of chronic enteropathy, chronic diarrhea, extensive intestinal resection, unresolved bowel obstruction/subobstruction, or extensive abdominopelvic radiation therapy were exclusion criteria. The protocol was approved by the ethics committee of Bicetre (Val de Marne, France), and signed informed consent was obtained from all patients prior to the inclusion. Complete blood cell counts were repeated twice weekly. Patients were evaluated weekly for toxicity while on study.
Treatment plan
Oxaliplatin was diluted in 250 ml 5% dextrose and administered as a 120-min infusion. CPT-11 was diluted in 250 ml 5% dextrose and administered as a 30-min infusion. A one-hour interval was left between the end of oxaliplatin infusion and the start of CPT-11 treatment. The dose of oxaliplatin was fixed at 85 mg/m 2 and the dose of CPT-11 was escalated according to the procedure indicated in Table 1 . No intra-patient dose escalation was allowed.
Treatments were done at the outpatient department and routinely administered on an ambulatory basis. Early cholinergic reaction to CPT-11 was prevented with a subcutaneous injection of 0.25 mg atropine sulfate at the start of CPT-11 infusion and could be repeated during or after CPT-11 infusion in case of cholinergic symptoms. Antiemetic therapy always contained at least the intravenous injection of 3 mg of granisetron before oxaliplatin infusion, eventually associated with 40 mg of methylprednisolone. In case of delayed emesis, the patients were treated with metoclopramide and/or prednisolone. No prevention of delayed diarrhea was attempted. Specific guidelines for the monitoring of delayed diarrhea included a diary report of the number of stools, and the early prescription of high-dose loperamide. Patients were instructed to start 4 mg loperamide therapy immediately after the first loose stool and 2 mg after each new loose stool regardless of the interval between stools. This antidiarrheal regimen was discontinued 12 hours after the last loose stool and was not to exceed 48 hours without physicians's examination. CPT-11 was continued alone in case of oxaliplatin discontinuation due to neurotoxicity or allergic reaction.
Evaluation of toxicity. Definitions of DLT and MTD
All toxicities, except peripheral sensory neuropathy, were graded using the National Cancer Institute Common Toxicity Criteria. Diarrhea was graded as previously described [17] Oxaliplatin neurosensory toxicity was described according to the specific grading proposed by Levi [19] . The DLTs were defined as grade 4 neutropenia lasting more than seven days, any febrile grade 3 or 4 neutropenia, grade 4 thrombocytopenia, grade 3 peripheral sensitive neuropathy, grade 4 vomiting, and grade 3 or 4 other non-hematologic toxicity (excluding alopecia). In case of DLT, the treatment was to be discontinuated until recovery of grade < 1, and, if clinically indicated, resumed for the subsequent cycle at the dose level immediately below that which resulted in the DLT. A minimum of three patients were entered at each dose level, with a minimum one week interval between the entry of the first patient and the next two patients of a given dose level The criteria to allow dose escalation to the next dose level were described in the first part of the study. The maximum tolerated dose (MTD) was defined as the dose resulting in at least three patients developing the same dose limiting toxicity at the first or the second administration.
The recommended dose was defined as the dose immediately below the MTD and was further examined in additional patients to confirm its toxicity and safety profile.
Assessment of response
An imaging assessment of tumoral target lesions was repeated every three cycles. Objective responses were recorded according to standard WHO.'UICC response criteria [20] , and were independently reviewed by an external panel of radiologists. Table 2 lists the characteristics of the 23 patients entered in the study. Most patients (65%) had a performance status of 0 to 1. All patients, but one with locally advanced and unresectable pancreatic cancer, had metastatic disease. One patient with rectal cancer had been previously treated by pelvic irradiation and was the unique patient with previous radiation therapy. Colorectal cancer patients represented the largest population included in the study (47%). All 11 CRC patients were pretreated with a 5-FU-based chemotherapy. Two of them (18%) had no evidence of clinical resistance to 5-FU. Four of them (36%) had objective response to 5-FU followed by disease progression within six months after 5-FU treatment. The other five (45%) CRC patients had experienced disease progression as best response under 5-FU treatment or progressed on adjuvant 5-FU and were thus considered as 5-FU-refractory. All six gastric cancer patients were resistant or refractory to 5-FU, cisplatin and anthracyclines. All patients had measurable disease and were evaluable for both toxicity and response.
Results
Patient population
Study treatment
A total of 186 cycles of treatment were administered through five dose levels of CPT-11 combined with 85 mg/m 2 oxaliplatin and most patients (65%) were treated as outpatients. No dose limiting toxicity was observed following the two first cycles in any of the nine patients included at the dose levels I, II, and III. An additional patient with metastatic gastric cancer was added at dose level III at the end of the study to ensure the safety of this dose level in PS 2 patients. He did not experience severe toxicity but was withdrawn from study after the first cycle because of disease progression. A total of 85 cycles were given in 10 patients at dose level IV with a median number of cycles per patient of 7 (range: 3-13) prior to recommend this dose level for phase II studies in PS 0-1 patients.
Reasons for study withdrawal
Thirteen patients were withdrawn from the study because of evidence of progressive disease, including one death on therapy. One patient with non-resectable liver metastases which appeared during 5-FU/FA adjuvant therapy had a partial response on the study treatment that allowed hepatic metastasectomy after 11 cycles. Two patients left the study for personal reasons (one returned to his country, one for inguinal hernia surgery). One pancreas cancer patient was withdrawn from the study because of an oxaliplatin allergic reaction after seven cycles. Six patients (5 CRC and 1 pancreas cancer patients responding to therapy and having received 8 to 12 cycles) were withdrawn for oxaliplatin-related neuro- sensory toxicity and continued CPT-11 alone for at least three cycles.
Dose-intensity
The oxaliplatin dose was fixed (85 mg/m 2 ). The starting dose of CPT-11 was maintained in 100% of patients (all cycles) at the dose levels I, II, and III, in 70% (7 of 10) of the patients and 86% (73 of 85) of cycles at dose level IV, and in 69% (20 of 29) of courses at dose level V. Five patients had early treatment discontinuation (<4 administrations) either due to progressive disease or patient refusal. The other 18 (78%) patients (10 CRC, 4 gastric, 3 pancreatic, 1 unknown primary) had a median number of 10 administrations (range 6-13). The median cumulative dose was 1375 mg/m 2 (150-2125) for CPT-11 and 765 mg/m 2 (85-1105) for oxaliplatin. No cycle delays were due to toxicity, except in one patient for febrile neutropenia, at the MTD level. The relative dose-intensities (given DI/planned DI) were calculated individually for all cycles given to each patient and are indicated in Table 1 .
Toxicity
Toxicity per patient, per dose level, and per cycle is presented in tables 3 and 4. Overall, acute toxicity was mild under dose level IV. At dose level IV, the main acute toxicities were grade 3-4 nausea and vomiting (40% of patients), grade 4 neutropenia (30% of patients), grade 4 diarrhea (30% of patients). Other toxicities with cumulative characteristics were neurosensory, anemia, thrombocytopenia, and alopecia. No lethal or lifethreatening toxicity was observed.
Hematologic toxicity
The frequency of hematologic adverse events for the 23 patients is listed in Tables 3 and 4 . The median onset of grade 4 neutropenia occurred on day 8, with a median duration of 4 days. One grade 4 neutropenia lasting longer than seven days was recorded at dose level V. No patient received prophylactic G-CSF, with only one patient receiving therapeutic G-CSF, and no patient required platelet transfusion. Grade 4 neutropenia occurred in 39% of patients and appeared to be dosedependent. At dose level 4, no grade 4 neutropenia was observed following the first two administrations but 30% of the patients experienced at least one grade 4 neutropenia episode during the remaining cycles. At the fifth dose level (200 mg/m 2 CPT-11), all three patients experienced grade 4 neutropenia. Based on the initial study criteria to define MTD, this dose-level was not the MTD because grade 4 neutropenias were short-lasting. However, at this dose level, neutrophils count recovery superior to 1 x 10 s */! and > 1.5 x 1O 9 /1 at day 15 ± 2 was not achieved in 10 of 29 (35%) and 19 of 29 (65%) cycles, respectively. Thus, neutropenia was considered as the dose-limiting toxicity because its characteristics were not compatible with the treatment plan. Of note, the recovery of neutrophils was not altered by scheduled retreatment at day 15, even in the absence of complete recovery. Based on our previous observation on the limiting hematotoxicity of the other available camptothecin derivative, topotecan [21] , the patients at the MTD level were retreated at day 15, without G-CSF, regardless of persistent mild/moderate neutropenia. This dosing method appeared feasible (median number of cycles per patient at the MTD: 11) but may be difficult to implement on a routine basis, given the reinforced monitoring required. Thrombocytopenia was sporadic, and had cumulative characteristics in only two patients. As platelets recovery to grade < 1 was delayed in these two patients, it contributed to reduced dose-intensity. Both patients remained with grade 1 thrombocytopenia two months after treatment discontinuation.
Infectious complications
Febrile neutropenia complicated six (3.2%) of the one hundred eighty-six cycles. Its sporadic nature was probably due to the short duration of severe neutropenia and the lack of concomitant diarrhea or mucositis. One patient at dose level I experienced isolated febrile neutropenia at the seventh cycle. Three episodes of febrile neutropenia occurred at dose level IV. All these episodes occurred in PS 2 patients. In contrast, none of the 39 cycles done in the five PS 0-1 patients at the same doselevel, and only 1 of 29 (3%) cycle in the 3 PS 0-1 patients at the MTD, was complicated with febrile neutropenia. No severe sepsis occurred.
Diarrhea
Delayed diarrhea was not the most severe toxicity since no grade 4 diarrhea was observed in any of the three patients and the 29 cycles at the highest dose-level. The importance of the control of the quality of the compliance to early active antidiarrheal treatment has been previously pointed out [22] and contributed to this good tolerance. The median number of days to the first loose stool was five and the median duration of grade 3-4 diarrhea was four days (range 1-13 days). In the patients experiencing severe diarrhea, subsequent dose reduction improved gastrointestinal tolerance. There was no evidence of cumulativity. In the absence of diarrhea at first cycle, diarrhea was never seen except one patient who experienced a Pseudomonas aeruginosa bowel infection at the sixth cycle. In contrast to febrile neutropenia, diarrhea was equally prevalent in PS 0-1 patients and in PS 2 patients (Table 5) .
Neuropathy
Neurosensory toxicity was prevalent as cumulative toxicity. Sensory neuropathy is a well-characterized sideeffect of oxaliplatin [23] . Its severity was characteristically preceded by progressively persistent paresthesias between cycles. The severity of symptoms was usually maximal two months after treatment interruption, followed by gradual reversibility of symptoms, as previously described [19, 23] . Severe cumulative neurosensory toxicity was not seen below 510 mg/m 2 (6 infusions) and was universal above 1020 mg/m 2 (12 infusions). Of note, a patient with grade 1 neuropathy had an accentuation of his symptoms starting immediately after partial hepatectomy, and lasting nine months, leading to grade 3 assessment and suggesting a relation with either anesthesia or surgery.
Other non-hematologic toxicities
Non-hematologic toxicity was generally mild. Grade 2 alopecia was universal. Nausea and vomiting were dosedependent and became dose-limiting at the MTD level: severe vomiting was not noted at dose level I, did not exceed 20%-30% of the cycles until dose level IV but increased to 65% of the cycles at the MTD level. Nausea, vomiting, and anorexia occurred immediately and could last the first week following treatment. Since the dose of oxaliplatin was fixed and only CPT-11 dose was escalated, the severity of acute vomiting observed in most patients at dose level IV and all patients at dose level V may be attributed to CPT-11 toxicity. A possible exacerbation of the CPT-11 cholinergic syndrome has been previously reported [24] in patients receiving CPT-11 without atropine prophylaxis, but was never noticed in our overall experience, probably because of our routine use of prophylactic subcutaneous injection of atropine before CPT-11 administration [17, 25] . Several patients (7 of 23, 30%) described a transient and mild dysarthria, always lasting less than 24 hours after treatment.
Antitumoral activity
Progressive disease at the first evaluation was observed in one patient with epidermoid oesophageal cancer (dose level I), two with gastric cancer (dose levels II and III), one with hepatocellular carcinoma (dose level III) and one with liver metastases of a tumor of unknown origin (dose level IV).
The antitumor activity in the three advanced pancreatic cancer patients was noteworthy. One of them had a six months stabilization, a second one with locally advanced tumor became resectable and the third, who had progressed on 5-FU and gemcitabine, achieved a partial response of liver metastases on oxaliplatin/ CPT-11. All three pancreatic cancer patients were treated at dose-level IV and were alive 12 months after diagnosis.
The patients with gastric cancer had been all pretreated with combination of 5-FU, cisplatin and either adriamycin or 4'epiadriamycin. The best response under treatment in advanced gastric cancer patients was complete response of cutaneous metastases (1 patient, fifth dose level), complete response of lung metastases with transient response of liver metastases (1 patient, third dose level), disease stabilization (1 patient at first and fourth dose levels) or progressive disease (1 patient at second and third dose levels).
Objective tumor responses were observed in 64% (7 of 11) of the CRC patients: three complete responses, and four partial responses with four disease stabilizations (lasting 11 to 24 weeks) were assessed, without any outright disease progression under treatment. Amongst the five 5-FU refractory patients, three experienced a partial response and two had disease stabilization lasting 20 and 24 weeks. Partial responses were documented in bulky liver metastases. Two of the complete responders had retroperitoneal lymph nodes as only metastatic site, the third patient had liver metastases. One of them was treated at dose level IV and the other two at dose level V. Retroperitoneal lymph nodes complete remissions were documented by CT-scans, and also confirmed by scintigraphy with 18-fluorodesoxy-glucose. Objective response was also observed at dose level I. As assessed in July 2000, the median time to disease progression in the 11 CRC patients was 8 months (range: 3-24 months). Their median survival was 33 months (range: 10-54) from diagnosis and was 17 months (range: 6-29) from inclusion in the study. Two of the CRC patients are alive two years after the diagnosis of the first metastasis.
Discussion
The first part of this phase I trial evaluated the toxicity of the every three weeks schedule of the combination of CPT-11 and oxaliplatin and has been previously described [17] . The recommended doses using the every three weeks schedule were 200 mg/m 2 for CPT-11 and 85 mg/m 2 for oxaliplatin and is now evaluated in a randomized phase II study by a US Intergroup. In the second part of the study, we evaluated the clinical toxicity of escalating doses of CPT-11 combined every two weeks with 85 mg/m 2 oxaliplatin in an attempt to increase the dose-intensity.
A relationship between the dose of CPT-11 and the antitumoral activity has been previously suggested [26] . A similar trend was observed during this study. However, antitumoral activity was reported at the first dose level.
Only CPT-11 dose was escalated in this phase I study. Interindividual variations in CPT-11 toxicity at a given dose level probably reflected in part the interindividual variations in CPT-11 and SN-38 pharmacokinetics in our population [27] .
To combine CPT-11 with oxaliplatin appeared more easily feasible than with cisplatin. Neutropenia was the dose limiting toxicity in both cases [17, [28] [29] [30] , and present study]. Thrombocytopenia was a dose-limiting toxicity with cisplatin, and if detectable, was never severe with oxaliplatin [17, and present study]. In comparison with the combination CPT-11 plus cisplatin, a 2-fold higher dose-intensity of CPT-11 was feasible, while the dose-intensity of the platinum derivative was also high (Table 6 ). This advantage over the combination with cisplatin might open new therapeutic perspectives in other diseases than CRC, such as pancreatic, gastric, ovarian or lung cancers. Table 6 Combinations of CPT-11 with oxaliplatin or cisplatin. In comparison with the two other studies combining CPT-11 and oxaliplatin [17, 18] , our present every other week schedule allowed to increase 1.3-to 1.5-fold the dose intensity for both CPT-11 and oxaliplatin. Hence, this schedule appeared as the most performant way to combine CPT-11 with a platinum derivative ( Table 6 ). The administration of CPT-11 175 mg/m 2 with oxaliplatin 85 mg/m 2 every two weeks, did not entail prophylactic G-CSF. In contrast, 31 of 36 (86%) of patients and 81 of 174 (46.5%) of cycles required G-CSF administration in a phase II study using a weekly administration of 80 mg/m 2 CPT-11 with 85 mg/m 2 oxaliplatin every two weeks [18] . Nausea and vomiting were less frequent than with the every three weeks schedule and this may be related to the lower dose per administration and thus a lower peak effect. The higher median cumulative dose of oxaliplatin (765 versus 596 mg/m 2 ) in this study in comparison with our every three weeks schedule experience is also of note and may account for the slight increase in severe neurosensory toxicity per patient (40% versus 33%). We observed more acute toxicity per patient at the recommended doses (175 mg/m 2 CPT-11 + 85 mg/m 2 oxaliplatin) than at the recommended doses of the every three weeks schedule (200 mg/m 2 CPT-11 + 85 mg/m 2 oxaliplatin): 50% versus 33% severe grade 3-4 neutropenia, 30% versus 17% with febrile neutropenia and 30% versus 17% grade 3-4 diarrhea. The toxicity per cycle was similar: 18% versus 11% severe grade 3-4 neutropenia, 4% versus 3% with febrile neutropenia and 7% versus 3% diarrhea. This increased toxicity may be explained by the differences in PS status of the patients included in these two different studies: PS 2 patients represented 35% of the patients included in this study and were only 5% in the study evaluating the every three weeks schedule. Hence, in this study, at dose level IV (175 mg/m 2 CPT-11), severe toxicity was 3-fold more frequent in PS 2 than in PS 0-1 patients (Table 5) . Thus, the performance status appeared a critical parameter for toxicity and two different CPT-11 starting doses, 175 and 150 mg/m 2 , are proposed in patients with PS 0-1 or PS 2, respectively.
In conclusion, this study indicates that CPT-11 and oxaliplatin can be combined every two weeks on an ambulatory basis at active doses without excessive toxicity. Oxaliplatin neuropathy was the main limiting cumulative toxicity but prolongation of treatment with CPT-11 alone was possible. The every two weeks schedule allowed the highest dose-intensities of both CPT-11 and oxaliplatin, so far. The absence of progressive CRC patients under treatment with CPT-11 and oxaliplatin, the reproducible evidence of antitumor activity in 5-FUrefractory patients and in patients with bulky liver metastases invite to evaluate the antitumor activity of this combination in CRC patients in a phase II study and to promptly evaluate the activity of this TS-independent regimen as first-line therapy in metastatic CRC patients.
